Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma
Status:
Not yet recruiting
Trial end date:
2027-12-01
Target enrollment:
Participant gender:
Summary
The main goal of this study is to establish the proportion of patients with objective
response to zimberelimab/domvanalimab in PD-1 R/R melanoma patients.